Aarushi Suneja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Aarushi Suneja has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Amira Salim
Genomic Medicine Institute, Cleveland Clinic Foundation Lerner Research Institute, Cleveland, USA; Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Department of Molecular Medicine, Cleveland, USA
1 shared publication - Claire Sonneborn
Department of Quantitative Health Sciences, Cleveland Clinic, OH
1 shared publication - Elise Hennessy
Department of Molecular Medicine (A. Salim), Cleveland Clinic Lerner College of Medicine, Case Western Reserve University; Genomic Medicine Institute (A. Salim, IFM), Lerner Research Institute, Cleveland Clinic; Center for Neurological Restoration (SB, MM, A. Suneja, ZA), Cleveland Clinic Neurological Institute; Quantitative Health Sciences (CS, OH), Lerner Research Institute, Cleveland Clinic, OH; and Neuroscience Institute (EH), Penn State Health Milton S. Hershey Medical Center, Hershey, PA
1 shared publication - Ignacio Fernandez Mata
Cleveland Clinic
1 shared publication - MaryAnn Mays
Headache & Facial Pain Section, Center for Neurological Restoration, Neurological Institute Cleveland Clinic Cleveland Ohio USA
1 shared publication - Olivia Hogue
Department of Quantitative Health Sciences Cleveland Clinic Cleveland Ohio USA
1 shared publication
Latest Publications
- 1 February 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (1) , e200373
Efficacy and Tolerability of Anti-CGRP Monoclonal Antibodies in Patients Aged ≥ 65 Years With Daily or Nondaily Migraine
Despite decreasing prevalence of migraine with advancing age, there remains a significant proportion of individuals aged ≥65 years with migraine. Treatment of this population is difficult and they are often excluded from clinical trials, limiting evidence regarding migraine treatment outcomes. Our objective is to assess the efficacy and tolerability of anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) therapies (erenumab, fremanezumab, and galcanezumab) in patients ≥65 years (O65) compared with patients p = 0.57) in the median MMD reduction between U65 (10 days [0.0-17.0]) and O65 (10 days [0.0-16.5]). Similarly, no difference was found among patients with nondaily migraine (p = 0.82) and patients with daily migraine (p = 0.59). HIT-6 scores decreased from severe to moderate/substantial impact for all groups. The daily and nondaily groups showed differences in meeting the 50% improvement threshold (nondaily U65, 67% vs daily U65, 54%, p < 0.0001; nondaily O65, 65% vs daily O65, 49%, p = 0.008). Side effects were reported (829/3,011), with a higher incidence in the U65 (22% O65, 28% U65). The most common side effects for both groups were injection site reaction/rash (40%) and constipation (25%). This retrospective analysis provides real-world evidence that there is no difference in the efficacy and tolerability of treatment with erenumab, fremanezumab, and galcanezumab in patients O65 when compared with patients U65 both with daily or nondaily migraine. These data may help guide the choice of migraine treatment in older populations.
- 1 February 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (1) , e200373
Efficacy and Tolerability of Anti-CGRP Monoclonal Antibodies in Patients Aged ≥ 65 Years With Daily or Nondaily Migraine
Despite decreasing prevalence of migraine with advancing age, there remains a significant proportion of individuals aged ≥65 years with migraine. Treatment of this population is difficult and they are often excluded from clinical trials, limiting evidence regarding migraine treatment outcomes. Our objective is to assess the efficacy and tolerability of anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) therapies (erenumab, fremanezumab, and galcanezumab) in patients ≥65 years (O65) compared with patients p = 0.57) in the median MMD reduction between U65 (10 days [0.0-17.0]) and O65 (10 days [0.0-16.5]). Similarly, no difference was found among patients with nondaily migraine (p = 0.82) and patients with daily migraine (p = 0.59). HIT-6 scores decreased from severe to moderate/substantial impact for all groups. The daily and nondaily groups showed differences in meeting the 50% improvement threshold (nondaily U65, 67% vs daily U65, 54%, p < 0.0001; nondaily O65, 65% vs daily O65, 49%, p = 0.008). Side effects were reported (829/3,011), with a higher incidence in the U65 (22% O65, 28% U65). The most common side effects for both groups were injection site reaction/rash (40%) and constipation (25%). This retrospective analysis provides real-world evidence that there is no difference in the efficacy and tolerability of treatment with erenumab, fremanezumab, and galcanezumab in patients O65 when compared with patients U65 both with daily or nondaily migraine. These data may help guide the choice of migraine treatment in older populations.